Vaxcell-Bio Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Vaxcell-Bio Therapeutics has a total shareholder equity of ₩78.3B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩83.1B and ₩4.9B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | n/a |
| Cash | ₩49.60b |
| Equity | ₩78.27b |
| Total liabilities | ₩4.87b |
| Total assets | ₩83.14b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A323990's short term assets (₩52.1B) exceed its short term liabilities (₩2.3B).
Long Term Liabilities: A323990's short term assets (₩52.1B) exceed its long term liabilities (₩2.5B).
Debt to Equity History and Analysis
Debt Level: A323990 is debt free.
Reducing Debt: A323990 has no debt compared to 5 years ago when its debt to equity ratio was 8820.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A323990 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A323990 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 24.3% each year.